Works matching IS 11707690 AND DT 2013 AND VI 31 AND IP 5
Results: 11
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
- Published in:
- 2013
- By:
- Publication type:
- journal article
How Much Should the NHS Pay for a QALY?
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 357, doi. 10.1007/s40273-013-0062-5
- By:
- Publication type:
- Article
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 427, doi. 10.1007/s40273-013-0048-3
- By:
- Publication type:
- Article
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 361, doi. 10.1007/s40273-013-0032-y
- By:
- Publication type:
- Article
The Authors' Reply to van Baal et al.: 'Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.'.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 375, doi. 10.1007/s40273-013-0046-5
- By:
- Publication type:
- Article
Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 403, doi. 10.1007/s40273-013-0043-8
- By:
- Publication type:
- Article
The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 445, doi. 10.1007/s40273-013-0041-x
- By:
- Publication type:
- Article
Optimal Global Value of Information Trials: Better Aligning Manufacturer and Decision Maker Interests and Enabling Feasible Risk Sharing.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 393, doi. 10.1007/s40273-013-0038-5
- By:
- Publication type:
- Article
Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 415, doi. 10.1007/s40273-013-0049-2
- By:
- Publication type:
- Article
Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 369, doi. 10.1007/s40273-013-0042-9
- By:
- Publication type:
- Article
Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia.
- Published in:
- PharmacoEconomics, 2013, v. 31, n. 5, p. 377, doi. 10.1007/s40273-013-0045-6
- By:
- Publication type:
- Article